Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]

QR Code

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]

Barabássy Á, Sebe B, Acsai K, et al. Neuropsychiatr Dis Treat. 2021;17:957–970. The authors have advised that there are errors in the first row of Table 5 on page 963. Cariprazine 4.5 mg column, the value “1 (0.0)” should&nbsp...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Barabássy Á, Sebe B, Acsai K, Laszlovszky I, Szatmári B, Earley WR, Németh G
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2021
Sujets:	cariprazine atypical antipsychotic schizophrenia safety and tolerability post hoc analysis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/cf336b8f9cd74908af6e74a46e31c7e7
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
par: Barabássy Á, et autres
Publié: (2021)

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
par: Octavian Vasiliu
Publié: (2021)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
par: Aubel T
Publié: (2021)

Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
par: Montes JM, et autres
Publié: (2021)

Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
par: Citrome L
Publié: (2018)

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
par: Aleksandr M. Reznik, et autres
Publié: (2020)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
par: Correll CU, et autres
Publié: (2019)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
par: Chih-Sung Liang, et autres
Publié: (2021)

Lack of tolerable treatment options for patients with schizophrenia
par: Citrome L, et autres
Publié: (2015)

Update on schizophrenia and bipolar disorder: focus on cariprazine
par: Roberts RJ, et autres
Publié: (2016)

New drugs in psychiatry - cariprazine, lurasidone, esketamine
par: Pożarowska Kinga, et autres
Publié: (2021)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
par: Borjanka Batinic, et autres
Publié: (2021)

A Random Forest Model for Predicting Social Functional Improvement in Chinese Patients with Schizophrenia After 3 Months of Atypical Antipsychotic Monopharmacy: A Cohort Study
par: Li Y, et autres
Publié: (2021)

Esquizofrenia y su asociación con enfermedades médicas crónicas
par: Orellana,Gricel, et autres
Publié: (2017)

Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
par: Ward K, et autres
Publié: (2019)

The Relationship between the Second-Generation Antipsychotics Efficacy and the Traditional Chinese Medicine Body Constitutions in Patients with Schizophrenia
par: Tzu-Pei Yeh, et autres
Publié: (2021)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
par: Leonid Mikhaylovich Bardenshteyn, et autres
Publié: (2010)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
par: Stephan Hjorth, et autres
Publié: (2021)

Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight
par: Findling RL, et autres
Publié: (2018)

Changes in Brain Structure, Function, and Network Properties in Patients With First-Episode Schizophrenia Treated With Antipsychotics
par: Ping Yin, et autres
Publié: (2021)

Altered Peripheral Immune Profiles in First-Episode, Drug-Free Patients With Schizophrenia: Response to Antipsychotic Medications
par: Lei Chen, et autres
Publié: (2021)

Diagnosis and Treatment of Depression in Patients with Schizophrenia
par: Sergey N. Mosolov
Publié: (2020)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
par: Montemagni C, et autres
Publié: (2016)

COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES
par: Shiraz Hussain, et autres
Publié: (2021)

A systematic review of the effects of psychiatric medications on social cognition
par: Zoë Haime, et autres
Publié: (2021)

A Multimodal Fusion Analysis of Pretreatment Anatomical and Functional Cortical Abnormalities in Responsive and Non-responsive Schizophrenia
par: Chenyang Yao, et autres
Publié: (2021)

Antipsychotics and risk of natural death in patients with schizophrenia
par: Chen Y, et autres
Publié: (2019)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
par: Zhang LL, et autres
Publié: (2016)

Schizophrenia research and treatment

Use of atypical antipsychotics in the elderly: a clinical review
par: Gareri P, et autres
Publié: (2014)

Atypical antipsychotics as add-on treatment in late-life depression
par: Cakir S, et autres
Publié: (2016)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
par: Emsley R, et autres
Publié: (2017)

Schizophrenia research
Publié: (1988)

Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
par: Moga S, et autres
Publié: (2021)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
par: Emsley R, et autres
Publié: (2018)

Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
par: Fitzgerald HM, et autres
Publié: (2021)

Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study
par: Patrick Köck, et autres
Publié: (2021)

Clinical schizophrenia & related psychoses
Publié: (2007)

Irreversible Primary Visual Cortex Impairment in a Mouse Model of High-Risk Schizophrenia
par: Chen X, et autres
Publié: (2021)

Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm
par: Cerveri G, et autres
Publié: (2019)